Financing channel feed – Endpoints News

Financing channel feed

Sequoia helps fuel Whole Biome's planned launch for 'medical probiotics' in $35M Series B

7 years ago

Third Rock unveils liquid biopsy biotech, leading $110M bet it can Thrive in early cancer detection

7 years ago

Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch

7 years ago

IPO boom: Antibody experts at Genmab outline global ambition in pitch for $500M

7 years ago

5 cash-hungry biotechs crowd into Nasdaq in search of a $600M-plus windfall

7 years ago

Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality

7 years ago

Ed Kaye is taking his fledgling biotech to Wall Street, looking for a new injection of cash

7 years ago

Treading on Nasdaq turf, NYSE cuts listing fees to woo biotech

7 years ago

Bicycle raises $61M in downsized IPO, joining fellow biotechs on Nasdaq who have hauled in $1.6B collectively

7 years ago

Ex-FDA commish Scott Gottlieb makes a quick jump back onto the money side of biotech

7 years ago

Additional backing arms Schrödinger with $110M in first venture round — shining a spotlight on its own pipeline

7 years ago

As UK biotech gains steam, Syncona launches new Treg player while Cambridge spinout expands Series A

7 years ago

All in on novel target GSK-3β, Actuate Therapeutics raises $21M+ to bankroll ambitious PhI/II

7 years ago

Microbiome upstart Vedanta gets an extra $18.5M in the bank, wrapping up $45.5 Series C round

7 years ago

They got bounced out of Alexion. Now David Hallal and Vikas Sinha are back with $150M and a focus on cell and gene therapies

7 years ago

Philogen who? A low profile but pharma-connected Italian-Swiss hybrid steps out with $68M for a final push over the PhIII finish line

7 years ago

Four biotechs haul in $303M+ from a fresh burst of IPOs

7 years ago

Belgium's liver-focused stem cell therapy developer Promethera raises $44M+ in latest round

7 years ago

Weeks after a Pfizer/Merck KGaA breakdown, Clovis gambles on a $175M loan to finish a global PhIII PARP/PD-1 combo study

7 years ago

Codiak Biosciences outlines a new focus for its exosome platform in $86M IPO filing

7 years ago

Vowing to spark a revolution in small molecule R&D, Vividion equips itself with an extra $82M for the final stretch to the clinic

7 years ago

A biotech fledgling cross-bred in France and Switzerland launches to take on liver problems of global dimensions

7 years ago

Eyeing RNAi potential in cancer and fibrosis, trans-Pacific biotech Sirnaomics lines up $47M Series C

7 years ago

Three biotechs reveal some secrets about themselves as they gun for $271M-plus in IPOs

7 years ago

First page Previous page 112 113 114115116 117 118 Next page Last page